| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.68B | -9.6% |
| Gross profit | ¥0.22B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -88.5% |
| Gross margin | 13.3% | Net margin 0.8% |
| Revenue Q/Q | +3.5% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.46B | 86.7% |
| R&D | ¥0.12B | 7.4% |
| SG&A | ¥0.07B | 4.4% |
| Tax & other | ¥-0.01B | -0.4% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林 ・ 太龙股份 ・ 金陵体育
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies